Fig. 5: Single-cell transcriptome of CD19-BBz CAR-NK products. | Nature Cancer

Fig. 5: Single-cell transcriptome of CD19-BBz CAR-NK products.

From: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Fig. 5

a, UMAP of 89,658 NK cells from 7 CAR-NK products, showing the formation of 6 subclusters shown in different colors, of which 2 products were linked to CR, 2 products were linked to PD, and 3 products (fCAR-NK) were analyzed after cryopreservation and revival. b, Top five DEGs in each identified subcluster. c, The fractions of each subcluster in each sample. d, UMAP showing the cell differentiation potential of each subcluster calculated using the CytoTRACE v2 algorithm. e, Expression distribution of gene sets related to cell proliferation and DNA replication using the UCell algorithm. The dashed circles in a, d and e highlight immune cell subtypes exhibiting significant differences in proportions between groups. f, Gene set enrichment analysis of DEGs in cluster NK0 and NK4 and mapping to UMAP for illustration (UCell scores were standardized by z-score). P value was calculated from empirical phenotype-based permutation test. NES, normalized enrichment score. g, Heat map of DEGs between CR, PD, and fCAR-NK groups, and mulberry plots showing their KEGG enrichment terms. P value was calculated from Fisher exact test. h, Evaluation models related to in vitro and in vivo efficacy.

Source data

Back to article page